319478-14-3

Basic information

• Product Name: 5-BROMOCHROMAN
• Synonyms: 5-BROMOCHROMAN;5-bromo-3,4-dihydro-2H-chromene;5-bromochromane
• CAS NO: 319478-14-3
• Molecular Formula: C9H9BrO
• Molecular Weight: 213.07
• Mol File: 319478-14-3.mol

Chemical Properties

• Boiling Point: 274.6±29.0 °C(Predicted)
• Appearance: /
• Density: 1.484±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 5-BROMOCHROMAN(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMOCHROMAN(319478-14-3)
• EPA Substance Registry System: 5-BROMOCHROMAN(319478-14-3)

Safety Data

• Hazardous Substances Data: 319478-14-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Manufacturing:
5-Bromochroman is used as a building block for the synthesis of various drugs and biologically active compounds due to its unique chemical structure and properties. It plays a crucial role in the development of anti-inflammatory and anticancer medications, contributing to the creation of novel therapeutic agents.
Used in Organic Synthesis:
As an intermediate in organic synthesis, 5-Bromochroman is utilized for the preparation of a wide range of chemical compounds. Its versatility in chemical reactions makes it a valuable component in the synthesis of various organic molecules.
Used in Fragrance and Flavoring Compounds Production:
5-Bromochroman is employed in the production of fragrance and flavoring compounds, capitalizing on its chemical properties to create a diverse array of scents and tastes for various applications in the perfumery and food industries.
Used in Research and Development of New Pharmaceuticals:
The potential pharmacological activity of 5-Bromochroman has been studied, making it a promising candidate for the development of new pharmaceuticals. Its unique properties and applications in drug synthesis contribute to ongoing research aimed at discovering innovative treatments and therapies.

Upstream product

• 52221-92-8 3-(2-bromo-phenyl)-propan-1-ol 
• 1016736-70-1 3-(3-bromophenoxy)propanenitrile 
• 591-20-8 3-Bromophenol 
• 22532-61-2 2-bromo-6-hydroxybenzaldehyde 
• 41389-15-5 2-allyl-3-bromophenol 
• 41388-50-5 1-(allyloxy)-3-bromobenzene 
• 1267362-25-3 ethyl (E)-3-(2-bromo-6-hydroxyphenyl)prop-2-enoate 

Downstream Products

• 13849-32-6 3,4-dihydro-5-hydroxy-2H-1-benzopyran 

Relevant articles and documents

Alcohol Etherification via Alkoxy Radicals Generated by Visible-Light Photoredox Catalysis

A mechanistically divergent method is described that, employing a commercially available hypervalent iodine(III) reagent, generates alkoxy radicals from 1°, 2°, and 3° alcohols and allows their use in the functionalization of C(sp3)-H and C(sp2)-H bonds. This visible-light photoredox catalysis produces alkyl ethers via 1,5/6-hydrogen atom transfer or aryl ethers via 1,5-addition. This mild methodology provides a practical strategy for the synthesis of acetals, orthoesters, tetrahydrofurans, and chromanes.

NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS

Disclosed are compounds of formula (I) or (II) that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER

Disclosed are compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, disclosed are compounds of Formula (I) and pharmaceutical compositions thereof, and methods of using the compounds and pharmaceutical compositions in, for example, methods of treating cancer.

Imidazo ring PAR4 antagonist and medical applications thereof

The invention relates to an imidazo ring compound represented by formula (I) or formula (II), or a pharmaceutically acceptable salt or ester or solvate thereof. The compound disclosed by the inventioncan be used for preparing medicines for preventing or treating thromboembolic diseases.

PRC2 INHIBITORS

The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention. (Formula (I))

Synthesizing method for 5-bromochroman

The invention provides a synthesizing method for 5-bromochroman, and relates to the technical field of synthesis of organic chemical intermediates. The synthesizing method comprises the following steps: (1) enabling bromophenol and acrylonitrile to react

Benzene C-H Etherification via Photocatalytic Hydrogen-Evolution Cross-Coupling Reaction

Aryl ethers can be constructed from the direct coupling between the benzene C-H bond and the alcohol O-H bond with the evolution of hydrogen via the synergistic merger of photocatalysis and cobalt catalysis. Utilizing the dual catalyst system consisting of 3-cyano-1-methylquinolinum photocatalyst and cobaloxime, intermolecular etherification of arenes with various alcohols and intramolecular alkoxylation of 3-phenylpropanols with formation of chromanes are accomplished. These reactions proceed at remarkably mild conditions, and the sole byproduct is equivalent hydrogen gas.